RVMD News and Press, Revolution Medicines Inc. From 08/03/23

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2023 on Tuesday, August 8...

2023-08-01 08:32:02 ET A clinical-stage oncology company, Revolution Medicines ( NASDAQ: RVMD ) plans to acquire EQRx ( NASDAQ: EQRX ) in an all-stock transaction intended to add more than $1B in net cash to Revolution Medicines’ balance sheet. The deal, which...

R evolution Medicines Expect s to Conduct Late-Stage Development of RAS(ON) I nhibitor Drug C andidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independe...

2023-07-11 18:56:04 ET Summary Revolution Medicines, Inc. is undoubtedly doing interesting science. However, I can name 10 companies that are doing equally interesting science but are valued at a fifth of Revolution Medicines stock. There is no way their early data justifies t...

REDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairma...

2023-05-08 23:17:08 ET Revolution Medicines, Inc. (RVMD) Q1 2023 Earnings Conference Call May 8, 2023 16:30 ET Company Participants Erin Graves - Senior Director of Corporate Communications and Investor Relations Mark Goldsmith - Chairman, President & Chief Execu...

2023-05-08 16:18:46 ET Revolution Medicines press release ( NASDAQ: RVMD ): Q1 GAAP EPS of -$0.72 beats by $0.10 . Revenue of $7.01M (-7.5% Y/Y) beats by $4.07M . Financial Guidance Revolution Medicines is updating its financial guidance and now expects ful...

First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RAS MULTI ), RMC-6291 (KRAS G12C ) and RMC-9805 (KRAS G12D ) – progressing on plan Appointment of chief medical officer and key leaders across late-stage development and commer...

REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2023 on Monday, May 8, 2023...

REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chair...